Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Smoking Cessation Strategies Targeting Specific Populations

  • Chun, Eun Mi (Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine)
  • Received : 2017.08.23
  • Accepted : 2018.01.02
  • Published : 2019.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Quitting smoking helps smokers maintain their health and extend their lifespan by 10 or more years. Treatment strategies for smoking cessation should be tailored to individual smokers with special needs based on their specific circumstances. It is recommended that pregnant women adopt smoking cessation through counseling and behavioral interventions because the safety of medications has yet to be established. Counseling is the main strategy for smoking cessation in adolescents and nicotine replacement therapy can be used with caution in individuals with serious nicotine dependence. It is important for smokers with psychiatric diseases to quit smoking following accurate assessment of their depression status. Nicotine replacement therapy, varenicline, and bupropion can be used for smoking cessation in smokers with psychiatric disorders. The incidence of cardiovascular disease decreased according to the smoking status and the duration of smoking cessation. In smokers with chronic obstructive pulmonary disease (COPD) who used a combination of counseling and pharmacotherapy the quitting rate was more than twice as high as subjects who used behavioral interventions alone. Varenicline can be used as the most effective anti-smoking drug by most smokers including those with psychiatric disorders, cardiovascular disease, and COPD.

Keywords

References

  1. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013;368:341-50. https://doi.org/10.1056/NEJMsa1211128
  2. Foulds J, Schmelzer AC, Steinberg MB. Treating tobacco dependence as a chronic illness and a key modifiable predictor of disease. Int J Clin Pract 2010;64:142-6. https://doi.org/10.1111/j.1742-1241.2009.02243.x
  3. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008;(2):CD000165.
  4. Korea Centers for Disease Control and Prevention. The sixth Korea National Health and Nutrition Examination Survey, 2015 [Internet]. Cheongju: Korea Centers for Disease Control and Prevention; 2015 [cited 2017 Dec 10]. Available from: http://knhanes.cdc.go.kr.
  5. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol 1990;163(1 Pt 2):285-91. https://doi.org/10.1016/0002-9378(90)90569-S
  6. Siu AL; U.S. Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015;163:622-34. https://doi.org/10.7326/M15-2023
  7. Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonardi-Bee J. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2012;(9):CD010078.
  8. Chamberlain C, O'Mara-Eves A, Porter J, Coleman T, Perlen SM, Thomas J, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev 2017;2:CD001055.
  9. Peirson L, Ali MU, Kenny M, Raina P, Sherifali D. Interventions for prevention and treatment of tobacco smoking in school-aged children and adolescents: a systematic review and meta-analysis. Prev Med 2016;85:20-31. https://doi.org/10.1016/j.ypmed.2015.12.004
  10. Stanton A, Grimshaw G. Tobacco cessation interventions for young people. Cochrane Database Syst Rev 2013;(8):CD003289.
  11. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. Smoking, smoking cessation, and major depression. JAMA 1990;264:1546-9. https://doi.org/10.1001/jama.1990.03450120058029
  12. Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 1995;25:95-101. https://doi.org/10.1007/BF02196920
  13. Banham L, Gilbody S. Smoking cessation in severe mental illness: what works? Addiction 2010;105:1176-89. https://doi.org/10.1111/j.1360-0443.2010.02946.x
  14. Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res 2011;129:94-5. https://doi.org/10.1016/j.schres.2011.02.003
  15. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013;(2):CD007253.
  16. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a doubleblind, randomised, placebo-controlled clinical trial. Lancet 2016;387:2507-20. https://doi.org/10.1016/S0140-6736(16)30272-0
  17. van Eerd EA, van der Meer RM, van Schayck OC, Kotz D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016;(8):CD010744.
  18. Kotz D, Viechtbauer W, Simpson CR, van Schayck OC, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. Thorax 2017;72:905-11. https://doi.org/10.1136/thoraxjnl-2017-210067
  19. Tottenborg SS, Thomsen RW, Johnsen SP, Nielsen H, Lange P. Determinants of smoking cessation in patients with COPD treated in the outpatient setting. Chest 2016;150:554-62. https://doi.org/10.1016/j.chest.2016.05.020
  20. Clair C, Rigotti NA, Porneala B, Fox CS, D'Agostino RB, Pencina MJ, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA 2013;309:1014-21. https://doi.org/10.1001/jama.2013.1644
  21. Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10:e002458.

Cited by

  1. Influence of Anxiety/Depression on the Subjective Evaluation of Cough in Patients with Chronic Obstructive Pulmonary Disease and Obesity vol.55, pp.5, 2019, https://doi.org/10.3390/medicina55050134
  2. Prevalence and analysis of tobacco use disorder in patients diagnosed with lung cancer vol.14, pp.9, 2019, https://doi.org/10.1371/journal.pone.0220127
  3. Smoking, as a Death Messenger vol.83, pp.4, 2019, https://doi.org/10.4046/trd.2020.0092
  4. Updated view on the treatment of chronic obstructive pulmonary disease in Korea vol.64, pp.3, 2019, https://doi.org/10.5124/jkma.2021.64.3.225
  5. Smoking prevention in adolescents: a cross-sectional and qualitative evaluation of a newly implemented prevention program in Switzerland vol.11, pp.12, 2019, https://doi.org/10.1136/bmjopen-2020-048319